# Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
Canonical URL: https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-penny-carlson-as-senior-vice-president-development--ec9a44a3
Ticker: KYMR
Company: Kymera
Source: Kymera
Published: 2026-06-08 20:01 EST
## Summary

Penny Carlson will oversee global clinical development operations across Kymera’s oral immunology portfolio Jeremy Chadwick will retire from his role as...

## Article Body
Penny Carlson will oversee global clinical development operations across Kymera’s oral immunology portfolio

Jeremy Chadwick will retire from his role as Chief Operating Officer

WATERTOWN, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Penny Carlson as Senior Vice President, Development Operations. Ms. Carlson brings more than two decades of biopharmaceutical leadership experience across clinical program management, study execution and data management, with a track record of advancing novel programs across multiple therapeutic areas. In her new role, she will oversee Kymera’s global clinical development operations as the Company advances multiple programs through mid- and late-stage development. Kymera also announced that Jeremy Chadwick will retire from his role as Chief Operating Officer and will remain as an advisor to the Company through the end of the year.

“We’re thrilled to welcome Penny to our team at this important stage in our growth. Her proven leadership and deep expertise in shaping global development strategies across large immunology indications will be instrumental as we continue to advance our pipeline through clinical development and toward commercialization,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “I would like to sincerely thank Jeremy for his dedication and many contributions to Kymera’s success throughout the company’s remarkable growth.”

“I was drawn to Kymera by its unwavering commitment to rigorous and ambitious scientific innovation and meaningful clinical impact,” said Ms. Carlson. “I am thrilled to be joining the company at such an exciting time of progress and opportunity, and I look forward to working with the talented team at Kymera to help advance these programs for patients and prepare the company for the next phase of growth and development.”

Prior to joining Kymera, Ms. Carlson served as Vice President and Head of Global Clinical Development Operations at Takeda, where she led a global organization responsible for the planning and execution of clinical trials across regions and therapeutic areas. During her tenure at Takeda, she held several senior leadership roles overseeing global clinical development operations and strategy. Earlier in her career, Ms. Carlson held leadership positions at Millennium Pharmaceuticals, Aileron Therapeutics, and other organizations across the pharmaceutical and biotechnology industry. She received a Bachelor of Science in Mathematics from Allegheny College.

About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn .

Investor Contact: Justine Koenigsberg investors@kymeratx.com 857-285-5300

Media Contact: Matthew Henson media@kymeratx.com 857-285-5300
## Recent Company News
- 2026-07-27 20:01 EST — [Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-terence-rooney-md-as-chief-medical-officer-93d7b265) — Source: Kymera
- 2026-07-07 11:00 EST — [Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-elizabeth-laws-ph-d-as-senior-vice-president-global-f322a3cc) — Source: Kymera
- 2026-06-25 11:00 EST — [Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-completes-enrollment-in-the-phase-2b-broaden2-trial-of-kt-62-eddcfec5) — Source: Kymera
- 2026-06-24 20:01 EST — [Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-felix-j-baker-ph-d-as-chairman-of-the-board-of-dire-f3d892d4) — Source: Kymera
- 2026-06-12 11:00 EST — [Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-presents-phase-1-data-in-healthy-japanese-adults-for-kt-621--a0403465) — Source: Kymera
## Related News
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)
- 2026-07-28 12:05 EST — GSK — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859)